EV Biologics (EV Biologics) Debt-to-Equity : 0.15 (As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Debt-to-Equity?

EV Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $6.47 Mil. EV Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2017 was $0.00 Mil. EV Biologics's Total Stockholders Equity for the quarter that ended in Dec. 2017 was $42.23 Mil. EV Biologics's debt to equity for the quarter that ended in Dec. 2017 was 0.15.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for EV Biologics's Debt-to-Equity or its related term are showing as below:

YECO's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.145
* Ranked among companies with meaningful Debt-to-Equity only.

EV Biologics Debt-to-Equity Historical Data

The historical data trend for EV Biologics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Debt-to-Equity Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Debt-to-Equity

0.40

0.25

0.27

0.87

2.78

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
Debt-to-Equity	Get a 7-Day Free Trial												0.87	1.14	1.55	2.78	0.15

Competitive Comparison of EV Biologics's Debt-to-Equity

For the Biotechnology subindustry, EV Biologics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EV Biologics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where EV Biologics's Debt-to-Equity falls into.

EV Biologics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

EV Biologics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.347	+	0)	/	3.719
	=	2.78

EV Biologics's Debt to Equity Ratio for the quarter that ended in Dec. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.469	+	0)	/	42.234
	=	0.15

EV Biologics (OTCPK:YECO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

EV Biologics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of EV Biologics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Debt-to-Equity

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3